menu
    • menu
    [{"orgOrder":0,"company":"IgNova","sponsor":"Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IGN-ES001","moa":"Unknown","graph1":"Neurology","graph2":"Undisclosed","graph3":"IgNova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"IgNova \/ Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis","highestDevelopmentStatusID":"1","companyTruncated":"IgNova \/ Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis"},{"orgOrder":0,"company":"IgNova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IgNova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgNova \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IgNova \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by IgNova

    Menu

    IgNova

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IgNova

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            IgNova

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IgNova Files Patent Application on Antibody Against COVID-19

                            Details : The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the infection process. IgNova's technology offers a safe, economical, and unlimited source of polyclonal antibodies...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IgNova

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            IgNova

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGN-ES001

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia

                            Details : IGN-ES001 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Chronic Pain.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 20, 2017

                            Lead Product(s) : IGN-ES001

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth